Do recombinant-engineered nanoparticle vaccines hold promise for the prevention of respiratory syncytial virus?

Nanomedicine (Lond). 2016;11(5):439-42. doi: 10.2217/nnm.16.2. Epub 2016 Feb 19.

Authors

Young-Tae Lee¹, Young-Man Kwon¹, Sang-Moo Kang¹

Affiliation

¹ Institute of Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.

PMID: 26893211
DOI: 10.2217/nnm.16.2

No abstract available

Keywords: RSV; recombinant nanoparticles; vaccines.

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Humans
Nanoparticles / therapeutic use*
Respiratory Syncytial Virus Infections / immunology
Respiratory Syncytial Virus Infections / prevention & control*
Respiratory Syncytial Virus Infections / virology
Respiratory Syncytial Viruses / immunology*
Respiratory Syncytial Viruses / pathogenicity
Viral Vaccines / immunology
Viral Vaccines / therapeutic use*

Substances

Viral Vaccines

Grants and funding